SG11202105195PA - Antibodies to human complement factor c2b and methods of use - Google Patents
Antibodies to human complement factor c2b and methods of useInfo
- Publication number
- SG11202105195PA SG11202105195PA SG11202105195PA SG11202105195PA SG11202105195PA SG 11202105195P A SG11202105195P A SG 11202105195PA SG 11202105195P A SG11202105195P A SG 11202105195PA SG 11202105195P A SG11202105195P A SG 11202105195PA SG 11202105195P A SG11202105195P A SG 11202105195PA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- methods
- complement factor
- human complement
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779102P | 2018-12-13 | 2018-12-13 | |
| PCT/IB2019/060802 WO2020121282A1 (en) | 2018-12-13 | 2019-12-13 | Antibodies to human complement factor c2b and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105195PA true SG11202105195PA (en) | 2021-06-29 |
Family
ID=69143627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105195PA SG11202105195PA (en) | 2018-12-13 | 2019-12-13 | Antibodies to human complement factor c2b and methods of use |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11161900B2 (en) |
| EP (2) | EP4375297A2 (en) |
| JP (2) | JP7110491B2 (en) |
| KR (1) | KR20210100688A (en) |
| CN (1) | CN113260375A (en) |
| AU (2) | AU2019397614B2 (en) |
| BR (1) | BR112021011107A2 (en) |
| CA (1) | CA3119655A1 (en) |
| EA (1) | EA202191658A1 (en) |
| IL (1) | IL283916A (en) |
| MX (1) | MX2021006864A (en) |
| SG (1) | SG11202105195PA (en) |
| WO (1) | WO2020121282A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019397614B2 (en) | 2018-12-13 | 2022-09-15 | Argenx Bvba | Antibodies to human complement factor C2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | Uses and compositions for treatment of rheumatoid arthritis |
| CA2654317A1 (en) * | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| EP2073898A1 (en) | 2006-10-10 | 2009-07-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Complement inhibition for improved nerve regeneration |
| US20090317400A1 (en) * | 2008-05-05 | 2009-12-24 | Krzysztof Masternak | Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| US9815890B2 (en) * | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| CA3131223C (en) * | 2011-05-04 | 2024-01-30 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| WO2013036778A2 (en) | 2011-09-07 | 2013-03-14 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| JP6543572B2 (en) * | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | Anti-complement C1s antibodies and their uses |
| WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| WO2014186622A2 (en) | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| LT2999714T (en) * | 2013-05-23 | 2020-07-10 | Broteio Pharma B.V. | Binding molecules that bind human complement factor c2 and uses thereof |
| CA2859114A1 (en) | 2013-08-29 | 2015-02-28 | International Automotive Components Group North America, Inc. | Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof |
| SG11201602522VA (en) * | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| MX2016005017A (en) * | 2013-10-17 | 2016-11-07 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation. |
| IL282401B (en) | 2013-12-12 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| KR102626877B1 (en) | 2014-11-05 | 2024-01-19 | 애넥슨, 인코포레이티드 | Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof |
| TW201726747A (en) | 2015-11-19 | 2017-08-01 | 艾伯維史坦森特瑞斯有限責任公司 | Novel anti-EMR2 antibodies and methods of use |
| KR20180093955A (en) | 2015-11-24 | 2018-08-22 | 애넥슨, 인코포레이티드 | Anti-complement Factor C1Q Fab fragments and uses thereof |
| MA53248A (en) | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | PH-ENHANCED ANTI-C5 ANTIBODIES |
| SG11201805579SA (en) | 2016-01-27 | 2018-08-30 | CSL Behring Lengnau AG | Recombinant igg fc multimers |
| WO2017196960A1 (en) | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| WO2018107109A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| TW201842931A (en) | 2017-03-14 | 2018-12-16 | 美商生物維瑞提夫美國公司 | Methods for treating complement-mediated diseases and disorders |
| JP2020517242A (en) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | Anti-ApoC3 antibody and method of using the same |
| WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| AU2019397614B2 (en) | 2018-12-13 | 2022-09-15 | Argenx Bvba | Antibodies to human complement factor C2b and methods of use |
-
2019
- 2019-12-13 AU AU2019397614A patent/AU2019397614B2/en active Active
- 2019-12-13 US US16/714,264 patent/US11161900B2/en active Active
- 2019-12-13 MX MX2021006864A patent/MX2021006864A/en unknown
- 2019-12-13 EP EP24164880.7A patent/EP4375297A2/en active Pending
- 2019-12-13 EP EP19832737.1A patent/EP3893924A1/en active Pending
- 2019-12-13 JP JP2021533300A patent/JP7110491B2/en active Active
- 2019-12-13 WO PCT/IB2019/060802 patent/WO2020121282A1/en unknown
- 2019-12-13 CN CN201980082826.8A patent/CN113260375A/en active Pending
- 2019-12-13 BR BR112021011107A patent/BR112021011107A2/en unknown
- 2019-12-13 SG SG11202105195PA patent/SG11202105195PA/en unknown
- 2019-12-13 KR KR1020217021353A patent/KR20210100688A/en not_active Application Discontinuation
- 2019-12-13 CA CA3119655A patent/CA3119655A1/en active Pending
- 2019-12-13 EA EA202191658A patent/EA202191658A1/en unknown
-
2021
- 2021-06-10 IL IL283916A patent/IL283916A/en unknown
- 2021-10-01 US US17/491,656 patent/US11591386B2/en active Active
-
2022
- 2022-01-10 US US17/572,518 patent/US11708403B2/en active Active
- 2022-07-20 JP JP2022115252A patent/JP2022160479A/en active Pending
- 2022-12-15 AU AU2022287637A patent/AU2022287637A1/en active Pending
-
2023
- 2023-06-07 US US18/330,903 patent/US20240002484A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7110491B2 (en) | 2022-08-01 |
| US20200239554A1 (en) | 2020-07-30 |
| MX2021006864A (en) | 2021-07-02 |
| EP4375297A2 (en) | 2024-05-29 |
| US11161900B2 (en) | 2021-11-02 |
| EP3893924A1 (en) | 2021-10-20 |
| WO2020121282A1 (en) | 2020-06-18 |
| KR20210100688A (en) | 2021-08-17 |
| AU2022287637A1 (en) | 2023-02-02 |
| EA202191658A1 (en) | 2021-11-03 |
| AU2019397614A1 (en) | 2021-06-03 |
| AU2019397614B2 (en) | 2022-09-15 |
| BR112021011107A2 (en) | 2021-12-14 |
| CA3119655A1 (en) | 2020-06-18 |
| US11708403B2 (en) | 2023-07-25 |
| US20220119509A1 (en) | 2022-04-21 |
| US20240002484A1 (en) | 2024-01-04 |
| US20220267424A1 (en) | 2022-08-25 |
| US11591386B2 (en) | 2023-02-28 |
| CN113260375A (en) | 2021-08-13 |
| IL283916A (en) | 2021-07-29 |
| JP2022512223A (en) | 2022-02-02 |
| JP2022160479A (en) | 2022-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
| PL3618863T3 (en) | Anti-tigit antibodies and methods of use thereof | |
| HUE062436T2 (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| IL287282A (en) | Anti-mertk antibodies and their methods of use | |
| IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| SG11202011146TA (en) | Drug-resistant immune cells and methods of use thereof | |
| IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| IL283916A (en) | Antibodies to human complement factor c2b and methods of use | |
| IL270894A (en) | Human antibodies to bet v 1 and methods of use thereof | |
| IL283136A (en) | Antibodies to mucin-16 and methods of use thereof | |
| IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| EP4061848A4 (en) | Anti-ror-2 antibodies and methods of use |